

Special Issue

Frontiers in Vaccines for COVID-19 and Related Coronavirus Diseases

Message from the Guest Editor

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been identified as the causative agent of Coronavirus Disease 2019 (COVID-19). The virus was first reported in Wuhan, China, and subsequently rapidly spread around the world, leading to one of the most severe pandemics in human history. By January 2021, more than 94 million confirmed cases have been reported in 191 countries and territories, and more than 2,029 million people have died. Worldwide efforts to stop transmission of SARS-CoV-2 and end the pandemic did not succeed in eradicating the virus, yet. Therefore, the development of effective intervention and prevention strategies is of uttermost importance. This Special Issue focuses on the following aspects: 1. Development of vaccines against COVID-19 and other coronaviruses 2. Factors influencing vaccine performance and outcome (e.g. environmental, comorbidities, gender). Dr. Sarah R. Leist

Guest Editor

Dr. Sarah R. Leist

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

Deadline for manuscript submissions

closed (31 May 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/74815

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).